TRUADVICE’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

TRUADVICE’s Portfolio GNOM Stock Details GNOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$126K	Buy	3,339 +291	+10%	+$13.2K	0.05%	229
2023 Q2	$138K	Sell	3,048 -318	-9%	-$15.9K	0.05%	259
2023 Q1	$165K	Buy	+3,366	New	+$173K	0.07%	249
2021 Q3	–	Sell	-41,261	Closed	-$3.65M	–	189
2021 Q2	$3.65M	Buy	41,261 +7,700	+23%	+$683K	0.8%	29
2021 Q1	$3.07M	Buy	+33,561	New	+$3.31M	0.91%	24

Other funds holding GNOM

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

OCM

One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Lido Advisors Los Angeles, California $32.7B AUM 19.2% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

MWAM

Manhattan West Asset Management Los Angeles, California $511M AUM 18.81% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

IWM

IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return

TRUADVICE's GNOM Position: Q3 2023 in Review

TRUADVICE increased its Global X Genomics & Biotechnology ETF (GNOM) stake by 9.5% in Q3 2023, buying an estimated $13.2K and bringing the position to 3,339 shares worth $126K. The position accounts for 0.05% of the portfolio, ranked #229.

TRUADVICE first reported a position in GNOM in Q1 2021 and has held it in 5 quarters since. The position peaked at $3.65M in Q2 2021. 63 funds tracked by Wall St. Rank hold GNOM as of Q3 2023.

TRUADVICE held 3,339 shares of Global X Genomics & Biotechnology ETF worth $126K as of Q3 2023.
TRUADVICE bought 291 Global X Genomics & Biotechnology ETF shares in Q3 2023, an estimated $13.2K.
Global X Genomics & Biotechnology ETF made up 0.05% of TRUADVICE's portfolio in Q3 2023, its #229 holding.
TRUADVICE first reported a position in Global X Genomics & Biotechnology ETF in Q1 2021 and has held it in 5 quarters since.
TRUADVICE's Global X Genomics & Biotechnology ETF position peaked at $3.65M in Q2 2021.
63 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q3 2023.

Based on TRUADVICE's 13F filing for Q3 2023, filed 13 Nov 2023.